Itero Biopharmaceuticals, a San Mateo, Calif. startup working with follow-on and therapeutic proteins and antibodies, raised a $21 million first round of financing and announced a partnership with Biological E., an Indian manufacturing firm.
Alongside its partner, Itero will begin development of differentiated follow-on proteins and work on securing patents and approvals for worldwide distribution, with multiple other product lines planned for the future.
SV Life Sciences, which is listed as the largest shareholder, and Panorama Capital led the round, with participation from VenturEast.
Trackback URL
